NYSEAMERICAN:SENSSenseonics Stock Price, Forecast & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Senseonics in the last year. There are currently 2 sell ratings, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Senseonics.

Senseonics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Senseonics.

Senseonics Holdings Inc (NYSEAMERICAN:SENS) released its quarterly earnings data on Tuesday, June, 9th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.09. The business had revenue of $0.03 million for the quarter, compared to analysts' expectations of $0.77 million. View Senseonics' earnings history.

8 brokers have issued 1-year price objectives for Senseonics' shares. Their forecasts range from $0.25 to $2.00. On average, they expect Senseonics' share price to reach $1.06 in the next year. This suggests a possible upside of 152.3% from the stock's current price. View analysts' price targets for Senseonics.

Headlines about SENS stock have trended very negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Senseonics earned a media sentiment score of -3.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Senseonics.

Senseonics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 25,150,000 shares, an increase of 5.1% from the June 15th total of 23,940,000 shares. Based on an average trading volume of 3,040,000 shares, the days-to-cover ratio is presently 8.3 days. Approximately 16.5% of the shares of the company are short sold. View Senseonics' Current Options Chain.

Some companies that are related to Senseonics include Profound Medical (PRN), Renalytix Ai (RENX), Volpara Health Tech (VHT), Akumin (AKU), MaxCyte (MXCT), Exagen (XGN), Yourgene Health (YGEN), Palatin Technologies (PTN), Oncimmune (ONC), Lexagene (LXG), Oncosil Medical (OSL), SQI Diagnostics (SQD), Genedrive (GDR), BARD1 Life Sciences (BD1) and Sernova (SVA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Senseonics investors own include Advanced Micro Devices (AMD), Agile Therapeutics (AGRX), Amarin (AMRN), Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), Tandem Diabetes Care (TNDM), VirnetX (VHC), Micron Technology (MU), Nabriva Therapeutics (NBRV) and Protalix Biotherapeutics (PLX).

Senseonics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SENS."

Shares of SENS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SENS stock can currently be purchased for approximately $0.42.

Senseonics has a market capitalization of $95.38 million. Senseonics employs 191 workers across the globe.

The official website for Senseonics is www.senseonics.com.

Senseonics' mailing address is 20451 Seneca Meadows Pkwy, GERMANTOWN, MD 20876-7005, United States. The company can be reached via phone at +1-301-5157260.